LOGIC GATES

Boolean Biology: The Future of Logic-Gated Cell and Gene Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Immuno-oncology

Immuno-Oncology at the Forefront of Cancer Medicine

David Alvaro, Ph.D.

Pharma's Almanac

Bioassays

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Anke Hartung, Ph.D.,

Tanvex CDMO

Vaccines

Delivering a Next-Generation COVID-19 Vaccine for Immunocompromised Patients and Novel Cancer Vaccines

David Dodd; Mark Newman, Ph.D.

GeoVax Inc.

Cell Therapy

Engineering Immune Cells to Realize the Promise of Cancer Cell Therapies

Beau Webber, Ph.D.

Luminary Therapeutics

Immuno-Oncology

Targeted Immune System Activation: A Paradigm Shift in Immuno-oncology

Dan Passeri, M.Sc., J.D.

Cue Biopharma

CAR-T

Enabling Greater Patient Access to CAR-T Cell Therapies with Off-the-Shelf Delivery Solutions

Ryan Larson, Ph.D.

Theranostics

Theranostic Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

Cell Therapy

Targeting Cancers by Leveraging the Biology of Gamma Delta T Cells

Bryan Kobel

TC Biopharm

Immuno-Oncology

Tuning the Myeloid Compartment with a Best-in-Class CDMO

Kiren Khanduga; Alicia Levey, Ph.D.

Pionyr Immunotherapeutics

Cell Therapy

Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner

Mark Shlomchik, M.D., Ph.D.

BlueSphere Bio

Immuno-Oncology

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Derek Hennecke

Inceptor Bio

Oncolytic Viruses

Coverting Viruses into Therapeutic Tools

OncoMyx Therapeutics

Biotech-CDMO Relationship

For mAbs, a Small Biotech Recognizes the Value in Lonza’s Expertise and Track Record

William Ben Jones, Ph.D.

Corvus Pharmaceuticals

Immuno-Oncology

Training the Immune System to Recognize Cancer Cells

Ian B. Walters, M.D., MBA

Portage Biotech, Inc.